Biblio
“A 10-Year Follow-Up of Adiposity and Dementia in Swedish Adults Aged 70 Years and Older.”, J Alzheimers Dis, vol. 63, no. 4, pp. 1325-1335, 2018.
, “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.”, Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
, “Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 71, no. 1, pp. 281-290, 2019.
, “Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1281-1291, 2017.
, “Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.”, J Alzheimers Dis, vol. 58, no. 3, pp. 821-828, 2017.
, “Association of Plasma Neurofilament Light Chain with Neocortical Amyloid-β Load and Cognitive Performance in Cognitively Normal Elderly Participants.”, J Alzheimers Dis, vol. 63, no. 2, pp. 479-487, 2018.
, “Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1395-1408, 2016.
, “Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.”, J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
, “Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type.”, J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
, “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
, “Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 2, pp. 467-475, 2023.
, “Cerebrospinal Fluid Sphingomyelins in Alzheimer's Disease, Neurodegeneration, and Neuroinflammation.”, J Alzheimers Dis, vol. 90, no. 2, pp. 667-680, 2022.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.”, J Alzheimers Dis, vol. 55, no. 1, pp. 303-313, 2017.
, “Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe.”, J Alzheimers Dis, vol. 60, no. 1, pp. 201-210, 2017.
, “Diagnostic Performance of Cerebrospinal Fluid Neurofilament Light Chain and Soluble Amyloid-β Protein Precursor β in the Subcortical Small Vessel Type of Dementia.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1515-1528, 2023.
, “Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology.”, J Alzheimers Dis, vol. 77, no. 3, pp. 1353-1368, 2020.
, “Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.”, J Alzheimers Dis, vol. 94, no. 4, pp. 1587-1605, 2023.
, “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
, “The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer's Disease.”, J Alzheimers Dis, vol. 56, no. 1, pp. 327-334, 2017.
,